Urinary tract infection following the use of BTK inhibitors: a real-world analysis of post-marketing surveillance data

References

• Eichhorst B, Dreyling M, Robak T, et al. Chronic lymphocytic leukemia: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2011;22(Suppl 6):vi50–vi54. doi: 10.1093/annonc/mdr377
   PubMed Web of Science ®Google Scholar
• Trotman J, Opat S, Gottlieb D, et al. Zanubrutinib for the treatment of patients with Waldenström macroglobulinemia: 3 years of follow-up. Blood. 2020;136(18):2027–2037. doi: 10.1182/blood.2020006449
   PubMed Web of Science ®Google Scholar
• Noy A, de Vos S, Thieblemont C, et al. Targeting Bruton tyrosine kinase with ibrutinib in relapsed/refractory marginal zone lymphoma. Blood. 2017;129(16):2224–2232. doi: 10.1182/blood-2016-10-747345
   PubMed Web of Science ®Google Scholar
• Kil LP, de Bruijn MJ, van Hulst JA, et al. Bruton’s tyrosine kinase mediated signaling enhances leukemogenesis in a mouse model for chronic lymphocytic leukemia. Am J Blood Res. 2013;3(1):71–83.
   PubMedGoogle Scholar
• de Rooij MF, Kuil A, Geest CR, et al. The clinically active BTK inhibitor PCI-32765 targets B-cell receptor- and chemokine-controlled adhesion and migration in chronic lymphocytic leukemia. Blood. 2012;119(11):2590–2594. doi: 10.1182/blood-2011-11-390989
   PubMed Web of Science ®Google Scholar
• Dreyling M, Jurczak W, Jerkeman M, et al. Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, Phase 3 study. Lancet. 2016;387(10020):770–778. doi: 10.1016/S0140-6736(15)00667-4
   PubMed Web of Science ®Google Scholar
• Byrd JC, Furman RR, Coutre SE, et al. Three-year follow-up of treatment-naïve and previously treated patients with CLL and SLL receiving single-agent ibrutinib. Blood. 2015;125(16):2497–2506. doi: 10.1182/blood-2014-10-606038
   PubMed Web of Science ®Google Scholar
• Sharman JP, Egyed M, Jurczak W, et al. Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzumab for treatment-naive chronic lymphocytic leukaemia (ELEVATE TN): a randomised, controlled, phase 3 trial. Lancet. 2020;395(10232):1278–1291. doi: 10.1016/S0140-6736(20)30262-2
   PubMed Web of Science ®Google Scholar
• O’Brien SM, Brown JR, Byrd JC, et al. Monitoring and managing BTK inhibitor treatment-related adverse events in clinical practice. Front Oncol. 2021;11:720704. doi: 10.3389/fonc.2021.720704
   PubMed Web of Science ®Google Scholar
• Xu W, Yang S, Zhou K, et al. Treatment of relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma with the BTK inhibitor zanubrutinib: phase 2, single-arm, multicenter study. J Hematol Oncol. 2020;13(1):48. doi: 10.1186/s13045-020-00884-4
   PubMed Web of Science ®Google Scholar
• Varughese T, Taur Y, Cohen N, et al. Serious infections in patients receiving ibrutinib for treatment of lymphoid cancer. Clin Infect Dis. 2018;67(5):687–692. doi: 10.1093/cid/ciy175
   PubMed Web of Science ®Google Scholar
• Byrd JC, Hillmen P, Ghia P, et al. Acalabrutinib versus ibrutinib in previously treated chronic lymphocytic leukemia: results of the first randomized Phase III trial. J Clin Oncol. 2021;39(31):3441–3452. doi: 10.1200/JCO.21.01210
   PubMed Web of Science ®Google Scholar
• Tada K, Gosho M. Increased risk of urinary tract infection and pyelonephritis under concomitant use of sodium-dependent glucose cotransporter 2 inhibitors with antidiabetic, antidyslipidemic, and antihypertensive drugs: an observational study. Fundam Clin Pharmacol. 2022;36(6):1106–1114. doi: 10.1111/fcp.12792
   PubMed Web of Science ®Google Scholar
• Böhm R, von Hehn L, Herdegen T, et al. OpenVigil FDA - Inspection of U.S. American adverse drug events pharmacovigilance data and novel clinical applications. PLoS One. 2016;11(6):e0157753. doi: 10.1371/journal.pone.0157753
   PubMed Web of Science ®Google Scholar
• Papazisis G, Spachos D, Siafis S, et al. Assessment of the safety signal for the abuse potential of pregabalin and gabapentin using the FAERS database and big data search analytics. Front Psychiatry. 2021;12:640264. doi: 10.3389/fpsyt.2021.640264
   PubMed Web of Science ®Google Scholar
• Bate A, Evans SJ. Quantitative signal detection using spontaneous ADR reporting. Pharmacoepidemiol Drug Saf. 2009;18(6):427–436. doi: 10.1002/pds.1742
   PubMed Web of Science ®Google Scholar
• Yang H, Yu X, An Z. Cutaneous toxicity associated with enfortumab vedotin: a real-word study leveraging U.S. Food and Drug Administration Adverse Event Reporting System. Front Oncol. 2022;11:801199. doi: 10.3389/fonc.2021.801199
   PubMed Web of Science ®Google Scholar
• Byrd JC, Furman RR, Coutre SE, et al. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med. 2013;369(1):32–42. doi: 10.1056/NEJMoa1215637
   PubMed Web of Science ®Google Scholar
• Burger JA, Tedeschi A, Barr PM, et al. Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia. N Engl J Med. 2015;373(25):2425–2437. doi: 10.1056/NEJMoa1509388
   PubMed Web of Science ®Google Scholar
• van Puijenbroek EP, Bate A, Leufkens HG, et al. A comparison of measures of disproportionality for signal detection in spontaneous reporting systems for adverse drug reactions. Pharmacoepidemiol Drug Saf. 2002;11(1):3–10. doi: 10.1002/pds.668
   PubMed Web of Science ®Google Scholar
• Tillman BF, Pauff JM, Satyanarayana G, et al. Systematic review of infectious events with the Bruton tyrosine kinase inhibitor ibrutinib in the treatment of hematologic malignancies. Eur J Haematol. 2018;100(4):325–334. doi: 10.1111/ejh.13020
   PubMed Web of Science ®Google Scholar
• Herbst S, Shah A, Mazon Moya M, et al. Phagocytosis-dependent activation of a TLR9-BTK-calcineurin-NFAT pathway co-ordinates innate immunity to Aspergillus fumigatus. EMBO Mol Med. 2015;7(3):240–258. doi: 10.15252/emmm.201404556
   PubMed Web of Science ®Google Scholar
• Stadler N, Hasibeder A, Lopez PA, et al. The Bruton tyrosine kinase inhibitor ibrutinib abrogates triggering receptor on myeloid cells 1-mediated neutrophil activation. Haematologica. 2017;102(5):e191–e194. doi: 10.3324/haematol.2016.152017
   PubMed Web of Science ®Google Scholar
• Jongstra-Bilen J, Puig Cano A, Hasija M, et al. Dual functions of Bruton’s tyrosine kinase and Tec kinase during Fcγ receptor-induced signaling and phagocytosis. J Immunol. 2008;181(1):288–298. doi: 10.4049/jimmunol.181.1.288
   PubMed Web of Science ®Google Scholar
• Strijbis K, Tafesse FG, Fairn GD, et al. Bruton’s tyrosine kinase (BTK) and Vav1 contribute to Dectin1-dependent phagocytosis of Candida albicans in macrophages. PLOS Pathog. 2013;9(6):e1003446. doi: 10.1371/journal.ppat.1003446
   PubMed Web of Science ®Google Scholar
• Pal Singh S, Dammeijer F, Hendriks RW. Role of Bruton’s tyrosine kinase in B cells and malignancies. Mol Cancer. 2018;17(1):57. doi: 10.1186/s12943-018-0779-z
   PubMed Web of Science ®Google Scholar
• Tam CS, Dimopoulos M, Garcia-Sanz R, et al. Pooled safety analysis of zanubrutinib monotherapy in patients with B-cell malignancies. Blood Adv. 2022;6(4):1296–1308. doi: 10.1182/bloodadvances.2021005621
   PubMed Web of Science ®Google Scholar